| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 01/28/2009 | EP2018861A1 5HT6-Ligands such as sulfonamide derivatives in drug-induced weight-gain |
| 01/28/2009 | EP2018860A1 Duloxetine composition |
| 01/28/2009 | EP2018859A1 Arylmethylene substituted N-acyl-beta-amino alcohols |
| 01/28/2009 | EP2018858A1 Compositions and methods for the treatment of primary and metastatic neoplastic diseases using arsenic trioxide |
| 01/28/2009 | EP2018857A1 Medical device and use of a pharmaceutical composition |
| 01/28/2009 | EP2018856A2 Multi-part medicinal product for wound cleansing and healing |
| 01/28/2009 | EP2018855A1 Pharmaceutical agent |
| 01/28/2009 | EP2018854A1 Novel combinations of neramexane for the treatment of neurodegenerative disorders |
| 01/28/2009 | EP2018853A1 Pharmaceutical compositions comprising a HMG COA reductase inhibitor |
| 01/28/2009 | EP2018852A1 Controlled-release formulations coated with aqueous dispersions of ethylcellulose |
| 01/28/2009 | EP2018851A1 Enhanced formulations of lamotrigine |
| 01/28/2009 | EP2018792A2 Substituted piperidino phenyloxazolidinones |
| 01/28/2009 | EP2018439A1 Personalizing cancer chemotherapy based on methylation and germ-line mutational analysis of brca-1 |
| 01/28/2009 | EP2018426A2 Rnai-mediated inhibition of tumor necrosis factor -related conditions |
| 01/28/2009 | EP2018395A1 Short interference ribonucleic acids for treating allegic diseases |
| 01/28/2009 | EP2018392A1 Pharmaceutically acceptable salts and polymorphic forms |
| 01/28/2009 | EP2018388A2 Bisadenosine compounds as adenosine a2a receptor agonists |
| 01/28/2009 | EP2018387A1 Thiazolyldihydroindazoles |
| 01/28/2009 | EP2018386A1 Thiazolyldihydroindazoles |
| 01/28/2009 | EP2018385A1 Thiazolyl-dihydroquinazolines |
| 01/28/2009 | EP2018384A2 Pyrimidine low molecular weight ligands for modulating hormone receptors |
| 01/28/2009 | EP2018383A1 Triazolopyrazine derivatives useful as anti-cancer agents |
| 01/28/2009 | EP2018382A2 Purine derivatives as adenosine receptor activator |
| 01/28/2009 | EP2018381A2 Use of 2-(purin-9-yl)-tetrahydofuran-3,4-diol derivatives as adenosine a2a receptor agonists |
| 01/28/2009 | EP2018380A2 Cns active fused bicycloheterocycle substituted azabicyclic alkane derivatives |
| 01/28/2009 | EP2018378A2 Heterocyclic inhibitors of 11-b hydroxyl steroid dehydrogenase type i and methods of using the same |
| 01/28/2009 | EP2018377A1 2-pyrazinone derivatives for the treatment of disease or condition in which inhibition of neutrophil elastase activity is beneficial. |
| 01/28/2009 | EP2018376A1 Benzylamine derivatives as cetp inhibitors |
| 01/28/2009 | EP2018375A1 2-pyridone derivatives for the treatment of disease or condition in which inhibition of neutrophil elastase activity is beneficial. |
| 01/28/2009 | EP2018372A2 Crystalline forms and processes for the preparation of phenyl-pyrazoles useful as modulators of the 5-ht2a serotonin receptor |
| 01/28/2009 | EP2018371A1 Primary amines and derivatives thereof as modulators of the 5-ht2a serotonin receptor useful for the treatment of disorders related thereto |
| 01/28/2009 | EP2018370A1 1,5-diphenylpyrazoles ii as hsp90 inhibitors |
| 01/28/2009 | EP2018368A1 Malonamide derivatives as gamma secretase inhibitors |
| 01/28/2009 | EP2018366A1 Hybrid molecules having mixed vitamin d receptor agonism and histone deacetylase inhibitory properties |
| 01/28/2009 | EP2018364A1 Therapeutic fluoroethyl ureas |
| 01/28/2009 | EP2018211A2 Veterinary pharmaceutical compositions for the treatment of pain and inflammation |
| 01/28/2009 | EP2018186A2 Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations thereof |
| 01/28/2009 | EP2018185A1 Use of mas-g-protein-coupled receptor agonists in the treatment of the metabolic syndrome, its components and its complications |
| 01/28/2009 | EP2018179A1 Use of antagonists of cxcl13 or cxcr5 for treating wounds or fibrotic diseases |
| 01/28/2009 | EP2018178A2 Administration of agonist-antagonist in opioid-dependent patients |
| 01/28/2009 | EP2018176A2 Kiwi extract |
| 01/28/2009 | EP2018171A1 The use of the salicylate as an antidote for paraquat intoxications in mammals |
| 01/28/2009 | EP2018170A2 Medication against breast cancer and related diseases |
| 01/28/2009 | EP2018167A2 Compositions and methods for fgf receptor kinases inhibitors |
| 01/28/2009 | EP2018166A2 Terephthalamate compounds and compositions, and their use as hiv integrase inhibitors |
| 01/28/2009 | EP2018165A1 Fgf-peceptor agonist dimeric compounds |
| 01/28/2009 | EP2018164A2 Use of combination preparations comprising antifungal agents |
| 01/28/2009 | EP2018163A2 Imaging agents and methods |
| 01/28/2009 | EP2018162A2 Methods for the delivery of a beta2 agonist to induce bronchodilation and formulations for use in the same |
| 01/28/2009 | EP2018158A1 New form of administration of racecadotril |
| 01/28/2009 | EP2018153A1 Liquid oral compositions |
| 01/28/2009 | EP2018152A2 Pre-mixed, ready-to-use pharmaceutical compositions |
| 01/28/2009 | EP2018151A1 Parenteral formulation comprising proton pump inhibitor sterilized in its final container by ionizing radiation |
| 01/28/2009 | EP2018150A1 Pharmaceutical composition having reduced abuse potential |
| 01/28/2009 | EP2018103A2 Methods and compositions for the treatment of infection or infectious colonization of the eyelid, ocular surface, skin or ear |
| 01/28/2009 | EP1915347B1 New 1 , 2 -diaryl pyrazoles useful as analgetic and anti-inflammatory agents |
| 01/28/2009 | EP1906987A4 Methods and compositions for emergency contraception using endothelin receptor antagonists |
| 01/28/2009 | EP1815006A4 Inhibitors of biotin protein ligase |
| 01/28/2009 | EP1814880B1 Imidazo[1,2-a]pyridine compounds, compositions, uses and methods related thereto |
| 01/28/2009 | EP1711508B1 6r-(3,6-dideoxy-l-arabino-hexopyranosyloxy)heptanoic acid, preparation process for the same and dauer effect thereof |
| 01/28/2009 | EP1673055B1 Vegetable substitute for lanolin |
| 01/28/2009 | EP1670761B1 Tetrahydro-naphthalene and urea derivatives |
| 01/28/2009 | EP1648473B1 Single dose fast dissolving azithromycin |
| 01/28/2009 | EP1608664B1 Non-cross-linking pyrrolo[2,1-c][1,4]benzodiazepines as potential antitumour agents and process thereof |
| 01/28/2009 | EP1585732A4 Spermicidal and/or antifungal composition and methods of using the same |
| 01/28/2009 | EP1553922B1 Salmeterol superfine formulation |
| 01/28/2009 | EP1542687B1 Small organic molecules that increase the activity of gelatinase a in ocular cells |
| 01/28/2009 | EP1495024B1 Dipyridodiazepinones as reverse transcriptase inhibitors |
| 01/28/2009 | EP1470826B1 Decoy-containing pharmaceutical compositions for the treatment of aneurysms |
| 01/28/2009 | EP1446400B1 Piperidine derivatives, process for preparation thereof, and pharmaceutical composition for alzheimer's disease containing the same |
| 01/28/2009 | EP1435927B1 Use of totarol for the treatment of pruritus |
| 01/28/2009 | EP1418910B1 Methods for inhibiting or reversing tau filament formation polymerization |
| 01/28/2009 | EP1315701B1 Process for the racemisation of 1-benzyl-4-(4-fluorophenyl)-3-hydroxymethyl-1,2,3,6-tetrahydropyridine to be used as intermediate in the synthesis of paroxetine |
| 01/28/2009 | EP1177181B1 Substituted bicyclic compounds |
| 01/28/2009 | EP1121135B1 Compositions of beta-glucans and specific immunoglobulins |
| 01/28/2009 | EP1073416B1 Use of inhaled no as anti-inflammatory agent |
| 01/28/2009 | EP0966443B1 Heteroaryl-hexanoic acid amide derivatives, their preparation and their use as selective inhibitors of mip-1-alpha binding to its ccr1 receptor |
| 01/28/2009 | CN101356436A Treatment and diagnosis of obligate intracellular pathogens |
| 01/28/2009 | CN101356193A Inhibition of the anti-FVIII immune response |
| 01/28/2009 | CN101356186A Prion-specific peptoid reagents |
| 01/28/2009 | CN101356185A Polymorphs of androgen receptor modulator - (N-3H-imidazo [4 , 5-B] pyridin-2-yl-methyl) -2-fluoro-4-methyl-3-oxo-4-aza-androst- l-en-17 . beta . -carboxamide |
| 01/28/2009 | CN101356179A Lipase inhibitors |
| 01/28/2009 | CN101356178A Compounds and compositions as PPAR modulators |
| 01/28/2009 | CN101356176A Therapeutic or prophylactic agent for functional bowel disorder |
| 01/28/2009 | CN101356174A Indol-3-yl-carbonyl-spiro-piperidine derivatives |
| 01/28/2009 | CN101356173A Novel pyridopyrazines and their use as modulators of kinases |
| 01/28/2009 | CN101356172A 激酶抑制剂 Kinase inhibitors |
| 01/28/2009 | CN101356170A Heterocyclic modulators of ATP-binding cassette transporters |
| 01/28/2009 | CN101356169A 吡嗪衍生物 Pyrazine derivatives |
| 01/28/2009 | CN101356168A Quinazolines useful as modulators of voltage gated ion channels |
| 01/28/2009 | CN101356167A Chroman compounds as 5-HT1B antagon |
| 01/28/2009 | CN101356164A Novel compounds |
| 01/28/2009 | CN101356163A Sulfanyl substituted phenyl methanones as glycine transporter 1 (GlyT-1) inhibitors for the treatment of neurological and neuropsychiatric disorders |
| 01/28/2009 | CN101356161A Heterocyclic CETP inhibitors |
| 01/28/2009 | CN101356160A Trisubstituted quinazolinone derivatives as vanilloid antagonists |
| 01/28/2009 | CN101356156A Aspartic protease inhibitors |
| 01/28/2009 | CN101356155A Phenoxy acetic acids as PPAR-delta activators |
| 01/28/2009 | CN101356152A Use of an aureolysin inhibitor for the treatment of inflammatory skin conditions characterised by colonisation with staphylococcus aureus |
| 01/28/2009 | CN101355969A Antiproliferative combination comprising CYC-682 and a cytotoxic agent |
| 01/28/2009 | CN101355968A Compositions and methods for treating thrombocytopenia |